Federal Trade Commission
-
Amgen, FTC Settlement Allows $28B Horizon Acquisition to Move Forward
Amgen and the Federal Trade Commission are settling the lawsuit the regulator filed to block the pharmaceutical giant’s $28 billion Horizon Therapeutics acquisition. As part of the settlement, Amgen agrees not to “bundle” its products with Horizon’s drugs in negotiations with health plans.
-
FTC Files Suit to Block Amgen’s $28B Buyout of Horizon Therapeutics
The Federal Trade Commission is suing to stop Amgen’s acquisition of Horizon Therapeutics. But rather than claiming product overlap, the agency contends Amgen will use its influence to keep at bay competition for Horizon’s products.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
GoodRx Illegally Sold Users’ Data to Google & Facebook, FTC Says
GoodRx failed to notify users that it sold their personal health information to Google, Facebook and other tech companies, the FTC claimed. The agency filed an order that prohibits GoodRx from sharing its users’ data with third parties for advertising purposes and requires the company to pay a $1.5 million penalty. GoodRx agreed to pay the settlement but did not admit to wrongdoing.
-
FTC accuses data company of tracking visits to reproductive health clinics
Kochava allegedly sold geolocation data from hundreds of millions of cell phones that showed people’s visits to reproductive health clinics, places of worship, homeless and domestic violence shelters and addiction recovery facilities.
-
Hospitals, MedCity Influencers, Legal
A myopic approach to merger regulation fails consumers instead of protecting them
Consolidated healthcare systems – even cross market systems – don’t have to raise their prices to have anticompetitive effects. They can leverage their size by using the volume of their purchases to extract discounts and other concessions from payers, national suppliers, and from labor pools.
-
Provider groups back Hackensack Meridian Health, Englewood Health’s appeal against merger delay
The American Hospital Association and Association of American Medical Colleges have filed an amicus brief in support of the New Jersey health systems that are appealing a court decision to delay their merger following a legal challenge from the FTC.
-
Illumina’s Grail buyout beats deadline, but legal and regulatory hurdles remain
In closing its Grail acquisition before U.S. and European regulators sign off, Illumina is taking a chance the deal will pass regulatory muster. It’s a potentially pricey gambit, as Illumina could face fines for its early action and there are no assurances that regulators will agree that the deal is not anticompetitive.
-
Illumina’s $7.1B Grail buyout is challenged by FTC on competitive grounds
The Federal Trade Commission is opposing Illumina’s proposed $7.1 billion Grail acquisition, arguing that it will reduce competition for multi-cancer early detection tests. Illumina disagrees with the regulator’s position and will oppose the FTC’s challenge.
-
FDA, FTC look to crack down on tactics that they say thwart biosimilars
In a joint statement, FDA Commissioner Stephen Hahn and FTC Chairman Joseph Simons said they would look into anticompetitive practices like preventing biosimilar makers from obtaining product samples and misleading communications about biosimilars’ safety and efficacy.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Martin Shkreli, his former company thwarted generic competition against toxoplasmosis drug, FTC says
In charges announced Monday, the agency says Vyera Pharmaceuticals – formerly Turing Pharma – used deals with distributors to prevent generic companies from obtaining samples and sales data for Daraprim. Vyera called the charges meritless.
-
Facing regulatory block, Illumina’s $1.2B PacBio buyout falls apart
The Federal Trade Commission had accused Illumina of seeking to monopolize the market for next-generation sequencing in its effort to acquire Pacific Biosciences, originally announced in November 2018.
-
BioPharma, Diagnostics, Policy
FTC moves to block Illumina’s $1.2B acquisition of PacBio
Federal regulators said they would seek to block the acquisition deal amid concerns that Illumina was seeking to eliminate PacBio as a competitor in the next-generation sequencing space.
-
Roche completes acquisition of Spark Therapeutics as regulators give go-ahead
The Federal Trade Commission and its U.K. counterpart concluded that Roche would not likely have an incentive to delay or discontinue development of Spark’s hemophilia A gene therapy. Roche markets a monoclonal antibody for the same disease.
-
Celgene to sell psoriasis drug to Amgen for $13.4B, clearing key hurdle to BMS deal
Bristol-Myers Squibb said Celgene would sell the drug, Otezla (apremilast), to Amgen. The pharmaceutical company had said it would seek a divestment of the drug to satisfy competition concerns from the FTC.
-
Florida-based Simple Health Plans shut down for selling “sham insurance”
According to the FTC, Simple Health Plans and its subsidiaries collected more than $100 million through deceptive marketing and sales practices that left many people stuck with thousands in unpaid medical costs.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
